ClinicalTrials.gg
RecruitingNCT02269592Updated May 7, 2026

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

An observational study in Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndromes and Hematological Malignancies, sponsored by Dana-Farber Cancer Institute. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by Dana-Farber Cancer Institute · Observational

How we know

From the registry’s dates

  • Started Aug 2014; still recruiting 12 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Monoclonal Gammopathy of Undetermined Significance with a site in United States — 15 open to participants now, 18 under way, none of them phase 3. Monoclonal Gammopathy of Undetermined Significance · United States.

Planned enrollment
Largest of 20
10,000 · median 217
Started
2014
with 2 others
Observational
20 of 76
10 open now
Primary completion
2027-12
later than 7 of 17 live
Registered
52nd of 76
by date
Lead sponsor
3 of 76
Dana-Farber Cancer Institute

Among the 76 studies in Monoclonal Gammopathy of Undetermined Significance with a site in United States, this one has the largest planned enrollment of the 20 observational ones that give a count, is one of 3 that started in 2014, is one of 20 observational ones, reaches primary completion later than 7 of the 17 other live ones, and was the 52nd registered.

Monoclonal Gammopathy of Undetermined Significance

102 studies on the registry are indexed under Monoclonal Gammopathy of Undetermined Significance; 28 are open to participants now.

Browse Monoclonal Gammopathy of Undetermined Significance studies →

Open to participants now

15 of the 76 studies in Monoclonal Gammopathy of Undetermined Significance with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Monoclonal Gammopathy of Undetermined Significance studies recruiting now, 18 (90%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Monoclonal Gammopathy of Undetermined Significance with a site in United States, or all of them as a file.
02

Study summary

Blood cancers occur when the molecules that control normal cell growth are damaged. Many of these changes can be detected by directly examining parts of the cancer or cells in blood. Several alterations that occur repeatedly in certain types of blood cancers have already been identified, and these discoveries have led to the development of new drugs that target those alterations. More remain to be discovered.

Some of these abnormalities include alterations in genes. Genes are the part of cells that contain the instructions which tell the investigators bodies how to grow and work, and determine physical characteristics such as hair and eye color. Genes are composed of DNA letters that spell out these instructions. Studies of the DNA molecules that make up the genes are called "molecular" analyses. Molecular analyses are ways of reading the DNA letters to identify errors in genes that may contribute to an increased risk of cancer or to the behavior of the cancer cells. Some changes in genes occur only in cancer cells. Others occur in the genes that are passed from parent to child. This research study will examine both kinds of genes. The best way to find these genes is to study large numbers of people. The investigators expect that as many 1000 individuals will enroll in this study.

This research study is trying to help doctors and scientists understand why cancer occurs and to develop ways to better treat and prevent it. To participate in this study the participant must have cancer now, had it in the past, or are at risk of developing cancer. The participant will not undergo tests or procedures that are not required as part of their routine clinical care. The investigators will ask the participant to provide an additional sample from tissue that is obtained for their clinical care including blood, bone marrow, or tissue sample. The investigators will also ask for a gentle scrape of the inside of their cheek, mouthwash or a skin sample to obtain their germline DNA

Read the detailed description

The purpose of this research study is to perform these molecular analyses on tissues (obtained from biopsies), blood, or other body fluids such as saliva. Importantly, this study will use tissue specimens that have already been collected as part of a participant's clinical care. The participant's tissue sample may be used to create a living tissue sample (called a "cell line") that can be grown in the laboratory. This allows researchers to have an unlimited supply of cells in the future without asking for more samples.

In this study, analyses will be performed on material only after all necessary clinical tests have been performed. In general, no additional procedures will be required. However, the investigators are asking the participant's permission to obtain one additional sample of blood (a few teaspoons), a gentle swab from the inside of their mouth or a sample of skin to obtain some cells. These are sources of normal, non-cancer cells which are needed for some types of analyses.

To fully understand the effects that molecular alterations have on blood cancers, they must be analyzed in the context of clinical behavior. Therefore, this study also asks the participant's permission to link the molecular alterations in their cancer or leukemia with clinical information that has been generated during the course of their clinical care. No additional clinical tests will be required. The investigator will ask to see the participant for follow up at regular interval to follow their risk of progression.

Some of participant's specimens as well as some of the material generated during the analysis of their tissues or blood may be useful for future study. The Investigator's are asking for the participant's permission to store these specimens and materials in a secure storage facility for possible later use.

Finally, rapid progress in understanding and treating cancer will occur when some of the molecular information derived from tissue and blood can be shared with other researchers. In particular, the National Institutes of Health (NIH) and other organizations have developed special data (information) repositories that analyze data and collect the results of certain types of genetic studies. These central banks will store genetic information and samples and give them to other researchers to do more studies. Therefore, the Investigators are also asking your permission to share your results with these special banks. The participant's information will be sent with only a code number attached. The participant's name or other directly identifiable information will not be given to central banks. There are many safeguards in place to protect the participant's information and samples while stored in repositories and used for research. The investigators do not think that there will be further risks to the participant's privacy and confidentiality by sharing this information with these banks. However, the investigator's cannot predict how genetic information will be used in the future.

03

Conditions studied

  • Monoclonal Gammopathy of Undetermined Significance (MGUS)
  • Myelodysplastic Syndromes
  • Hematological Malignancies
  • B-cell Malignancy, Low-grade
  • Myelodysplastic Syndrome With Low-grade Lesions
  • IgG Monoclonal Gammopathy of Uncertain Significance
  • Smoldering Multiple Myeloma
  • Waldenstrom Macroglobulinemia

Keywords

  • MGUS
  • Smoldering Myeloma
  • Acute Myeloid Leukemia
  • Waldenstrom Macroglobulinemia
  • Monoclonal Gammopathy of Undermined Significance
  • Monoclonal B cell lymphocytosis
  • Smoldering Multiple Myeloma
  • Myelodysplastic syndromes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with Known or Suspected Precursor Hematological Cancer

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Known or Suspected Precursor Hematological Cancer
  • Including the following subgroups of diseases:

    • Early MDS, including -confirmed MDS (IPSS Low/Int-1; IPSS-R Very Low/Low) and idiopathic cytopenias of undetermined significance (ICUS);
    • Asymptomatic Multiple Myeloma and Waldenstrom Macroglobulinemia such as monoclonal gammopathy of undermined significance (MGUS) or Smoldering Multiple Myeloma (SMM or SWM);
    • Monoclonal B cell lymphocytosis (MBL);
    • Early stage asymptomatic low-grade lymphomas; or
    • Other precursor conditions or clonal genetic abnormalities of the blood/bone marrow that do not meet criteria for symptomatic hematological , or patients exposed to prior chemotherapies (e. g., alkylating agents, platinum derivatives, taxanes, topo-2 inhibitors, anti-metabolites, systemic radioisotopes).
  • Patients must be at least 18 years of age to participate in this research.
  • Inclusion of Women and Minorities -- In accordance with NIH guidelines, women and members of minority groups and their subpopulations will be included in this protocol.

Exclusion criteria

Exclusion Criteria:

  • Patients with Known or Suspected Precursor Hematological Cancer are NOT EXCLUDED
  • Evidence of symptomatic or active hematological . Patients enrolled on clinical trials for precursor diseases are NOT excluded from this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Specimen Collection

    Patients' tumor tissue including bone marrow, blood, buccal swab or mouthwash, lymph node, urine or other specimens will be collected from patients who consent to the protocol

06

What researchers measure

Primary outcomes

  1. Identify molecular changes in cells of patients with precursor hematological malignancies

    Time frame: 10 years

07

Study locations

7 of 7 sites recruiting
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02115, United States
    Recruiting
    • Irene Ghobrial, MD · Contactprecursor@partners.org · 617-632-4198
    • Irene Ghobrial, MD · Principal investigator
  • Dana Farber Cancer Institute at St. Elizabeth's
    Brighton, Massachusetts 02135, United States
    Recruiting
    • Joseph Grider · Contact
    • Olga Kozyreva, MD · Principal investigator
  • Dana Farber Cancer Institute at Merrimack Valley
    Methuen, Massachusetts 01844, United States
    Recruiting
    • Saida Hussain · Contact
    • Pedro Sanz-Altamira, MD · Principal investigator
  • Dana Farber Cancer Institute at Milford Regional Medical Center
    Milford, Massachusetts 01757, United States
    Recruiting
    • Laura Melancon · Contact
    • Michael Constantine, MD · Principal investigator
  • Dana Farber Cancer Institute at South Shore
    Weymouth, Massachusetts 02190, United States
    Recruiting
    • Rebeka Lovato · Contact
    • Irene Ghobrial, MD · Principal investigator
  • West Michigan Cancer Center
    Kalamazoo, Michigan 49007, United States
    Recruiting
    • Kathleen Allen · Contactkallen@wmcc.org · 269-373-7452
    • Mohammad Omaira, MD · Principal investigator
  • Dana Farber/New Hampshire Oncology-Hematology
    Londonderry, New Hampshire 03053, United States
    Recruiting
    • Shannon Peabody · Contact
    • Jeanna Walsh, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2014 (actual). Primary completion is estimated for Dec 2027, 160 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2014
First posted
Oct 21, 2014
StartActual
Aug 2014
Primary completionEst.
Dec 2027
CompletionEst.
Sep 2030
Last update
May 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02269592
Collaborators
The Leukemia and Lymphoma Society
Responsible party
Irene Ghobrial, MD (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Oct 21, 2014
Start date
Aug 2014
Primary completion
Dec 2027 (estimated)
Completion
Sep 2030 (estimated)
Last update
May 7, 2026

Study contacts

Irene Ghobrial, MD
Contact
precursor@partners.org
617-632-4198
Irene Ghobrial, MD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion